IGF-DES

Understanding the IGF-1 DES Variant

IGF-1 DES is a naturally occurring analogue of Insulin-like Growth Factor-I (IGF-I), characterized by the cleavage of the Gly-Pro-Glu tripeptide from the N-terminus of the parent molecule. This variant has been isolated from human brain tissue, pig uterine tissue, and bovine colostrum. Relative to native IGF-I, IGF-1 DES is 10 times more potent at stimulating cellular proliferation and growth (hypertrophy). This superior efficacy is due to its lack of binding affinity for IGF-I binding proteins (IGFBPs), resulting in excellent systemic bioavailability. The peptide is being investigated for its ability to promote anabolism in wasting syndromes (catabolic conditions) and for the treatment of inflammatory bowel diseases.

The potential for IGF-1 DES to treat various neurological and neurodevelopmental disorders has generated considerable scientific interest. Researchers studying autism spectrum disorders (ASDs) have shown that IGF-I and its analogues can positively affect the health and integrity of synaptic neurons. Animal studies involving autism have demonstrated that both IGF-I and IGF-1 DES successfully alleviated symptoms and improved various behavioral measures.

Key Research Areas for IGF-1 DES

IGF-1 DES: Enhanced Biological Function Over IGF-I

The minute change in IGF-1 DES—the removal of just the three N-terminal amino acids—yields significant functional benefits. Studies indicate that IGF-1 DES displays zero binding affinity for the IGF-I binding proteins (IGFBPs) present in the blood and throughout the body's tissues. Consequently, at physiological pH, all IGF-1 DES circulating in the system is free and available to engage with its cellular receptors. This characteristic allows IGF-1 DES to exert significantly stronger biological effects at lower concentrations compared to standard IGF-I. These enhanced potency characteristics have been validated through pig studies and mammalian cell culture experiments.

A major functional benefit of IGF-1 DES is its sustained activity profile resulting from reduced clearance by IGFBPs. IGF-1 DES exhibits a notably longer time to onset, a higher peak of activity, and a more prolonged duration of action compared to standard IGF-I. This extended efficacy profile suggests therapeutic potential for managing conditions of elevated blood sugar (hyperglycemia).

Pig research shows that IGF-1 variants with low IGFBP affinity produce more pronounced growth-promoting effects. The anabolic capacity of IGF-1 DES remains effective even when the environment involves restricted calorie intake. Rat studies indicate that just 14 days of IGF-1 administration is sufficient to yield substantial improvements in body weight, nitrogen balance, and food conversion efficiency. The level of effectiveness is critically dependent on accurate dosing, as evidence suggests that excessive IGF-1 levels can reduce its efficacy. Researchers propose that IGF-1 DES offers utility for treating patients with chronic illnesses and those who cannot maintain adequate nutritional intake. As a more enduring and potent glucose-lowering agent, IGF-1 DES reduces blood sugar levels more quickly after administration. This is the rationale for investigating IGF-1 DES as a potential treatment for Type II diabetes, offering an alternative that may avoid the extended adverse effects associated with long-term insulin therapy.

IGF-1 DES Research and Neurological Disease

Scientific evidence has long established that IGF-I exerts critical effects on neuron growth, differentiation, and survival. The peptide is an essential component involved in memory, learning, and related cognitive functions. IGF-I holds particular importance for the structural integrity and proper function of mature nerve cells. Research confirms that IGF-I is essential for maintaining appropriate levels of pre-synaptic vesicles, which are structures that govern neurotransmitter release. A deficiency in IGF-I leads to disruption of synaptic development, which compromises the maintenance of synaptic structure. Insufficient IGF-I during early development results in abnormalities in post-synaptic density and causes deficits in the long-term regulation of synaptic transmission.

IGF-1 DES and Autism

Research suggests that IGF-I may play an integral role in the pathology of various neurological disorders, including autism. Children with autism often display reduced concentrations of IGF-I in the brain compared to neurotypical children. This specific deficit appears most critical during early developmental stages and may interrupt normal brain development, contributing to the presentation of autism symptoms.

Mouse models of autism indicate that IGF-II and its analogues, such as IGF-1 DES, are capable of reversing all associated behavioral deficits. Mice treated with IGF-II for only five days maintained sustained improvements in compulsive conditioning, showed reduced repetitive/compulsive behaviors, exhibited improved grooming patterns, and enhanced spatial memory processing. These positive outcomes remained stable after the treatment was discontinued.

Immune Function and IGF-1 DES Research

Immune cells, including neutrophils, T cells, B cells, and dendritic cells, express IGF-I receptors on their surface. Research demonstrates that IGF-1 DES can enhance immune system function. IGF-1 DES is more potent in stimulating macrophages and neutrophils to clear pathogens. In all studies examined, IGF-1 DES proved more effective than standard IGF-I. This potentiated effect could be a valuable adjunctive treatment alongside antibiotic and other antimicrobial therapies in managing infection. Findings show that higher systemic IGF-I levels correlate with improved digestive tract function by supporting mucosal growth and maintaining barrier integrity. The role of the peptide in immune system function is highly promising and critical.

Cognitive Benefits of IGF-1 DES in Aging

IGF-I is crucial for development in both children and adults. In adult populations, the peptide primarily influences skeletal muscle enlargement (hypertrophy). For pediatric applications, IGF-1 DES displays a stronger therapeutic potential compared to standard IGF-I. Molecules similar to IGF-1 DES also cross the blood-brain barrier with greater ease than native IGF-I. In adults, both IGF-1 and its variants have demonstrated the ability to reduce beta-amyloid accumulation in the brain, suggesting potential utility for conditions like Parkinson's disease and Alzheimer's disease, among others.

The evidence clearly suggests that IGF-I and related compounds provide benefits for treating conditions that impact cognitive health. These applications extend beyond disease treatment to enhancing memory and learning capabilities, and potentially slowing the natural decline of these functions with age. Such benefits could significantly enhance both the duration (lifespan) and quality (healthspan) of life in the aging population. Research findings indicate that IGF-1 DES produces approximately a 40% enhancement in excitatory synaptic transmission. Another research group has shown that dendritic spine growth in hippocampal neurons is highly sensitive to IGF-I concentration relative to synaptic function.

IGF-1 DES: A Molecule of Interest

IGF-1 DES is a promising therapeutic agent for various conditions linked to IGF-I activity, including neuroprotection and enhanced skeletal muscle growth. Its primary differentiating feature is its non-binding characteristic to IGFBPs, which enables it to penetrate the blood-brain barrier following subcutaneous injection. IGF-1 DES is generating significantly heightened interest among researchers studying neurodevelopment, stroke, cancer, wound healing, autism, and diabetes management.

IGF-1 DES is associated with low to moderate adverse effects. Its oral form has poor, while its injectable form has excellent, subcutaneous bioavailability in mice. Dosage translation from mouse models to humans is not directly scalable. IGF-1 DES offers benefits surpassing standard IGF-I as a research chemical available only to authorized researchers.

These findings are consistent with the hypothesis that autism likely results from synaptic transmission dysfunction. IGF-I and its analogues show therapeutic utility in managing neurodevelopmental disorders such as Fragile X syndrome, Tuberous Sclerosis, and Angelman syndrome. The advantages of IGF-1 DES, combined with its superior brain penetration ability, position it as an ideal candidate for investigating various therapeutic approaches for these conditions.

IGF-1 DES Research and Cancer

A key feature of malignant cells is their uncontrolled or undifferentiated state at various degrees of specialization. This complexity complicates treatment and causes functional deterioration. However, undifferentiated cells can also be more susceptible to treatments like radiation or chemotherapy, although they typically replicate faster. Inducing differentiation in cancer cells could potentially slow tumor growth. Research involving chicken leukemia cells demonstrates that cells treated with IGF-I and IGF-1 DES halted tumor growth by promoting differentiation.

Potential for Enhanced Wound Healing with IGF-1 DES

Skin dermal fibroblasts are the primary cell population responsible for tissue repair after physical damage. These cells are essential for synthesizing the necessary matrix for new tissue development. Scientific research has established that a certain protein significantly reduces the effect of IGF-I on its cellular receptors. Studies suggest that inflammatory cells present near wounds can positively influence the healing process. By administering peptides that are not affected by IGF-I binding proteins, it may be possible to mitigate inflammation and potentially improve healing outcomes in compromised tissues or environments with restricted blood flow. In research settings, this has the potential to accelerate wound recovery.

Article Author

The content presented above was researched, edited, and organized by Dr. Logan, M.D. Dr. Logan holds a medical doctorate from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Scientific Journal Author

Dr. Clemmons’ clinical practice and research are dedicated to growth hormone and IGF-I, specifically focusing on patients presenting with hypersecreting pituitary tumors and those with hypopituitarism. Dr. Clemmons is actively involved in investigative endocrinology practice and clinical research, in addition to providing clinical education. His foundational research aims to define the cellular and molecular mechanisms by which insulin-like growth factors promote cellular differentiation and proliferation. Dr. Clemmons has a specialized focus on how cells exhibiting abnormal proliferation respond to stimulation by these growth factors. He conducts clinical studies employing new methodologies to evaluate the effects of these factors in patients with diabetic nephropathy and retinopathy. His research interests include the combined assessment of IGF-I and growth hormone in patients presenting with hypopituitarism and those with pituitary tumors characterized by hypersecretion.

Dr. Clemmons is widely recognized as a prominent scientist in the research and development of DES and IGF-I. He does not participate in product endorsement, explanation, or advocacy for the use, sale, or purchase of this product for any reason. Peptide Sciences has no implied or explicit relationship, affiliation, or sponsorship with Dr. Clemmons. Dr. Clemmons is referenced here under the referenced citations solely to acknowledge, recognize, and credit the extensive research and development work conducted by the scientific community.

Referenced Citations

• F. J. Ballard, J. C. Wallace, G. L. Francis, L. C. Read, and F. M. Tomas, "Des(1-3)IGF-I: a truncated variant of insulin-like growth factor-I," Int. J. Biochem. Cell Biol., vol. 28, no. 10, pp. 1085–1087, Oct. 1996
• F. M. Tomas, P. C. Walton, F. R. Dunshea, and F. J. Ballard, "IGF-I variants that bind minimally to IGF-binding proteins display more potent and extended hypoglycaemic action compared to native IGF-I in pigs and marmoset monkeys," J. Endocrinol., vol. 155, no. 2, pp. 377–386, Nov. 1997
• P. E. Walton, F. R. Dunshea, and F. J. Ballard, "In vivo actions of IGF analogues with reduced affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness," Prog. Growth Factor Res., vol. 6, no. 2–4, pp. 385–395, 1995
• F. J. Ballard, P. C. Walton, S. Bastian, F. M. Tomas, J. C. Wallace, and G. L. Francis, "Effects of interactions between IGFBPs and IGFs on the plasma clearance and in vivo biological activities of IGFs and IGF analogs," Growth Regul., vol. 3, no. 1, pp. 40–44, Mar. 1993
• R. Camboni, "New experimental treatments for core social domain in autism spectrum disorders," Front. Pediatr., vol. 2, p. 61, 2014
• J. Costales and A. Kolevzon, "The Therapeutic Potential of Insulin-Like Growth Factor-1 in Central Nervous System Disorders," Neurosci. Biobehav. Rev., vol. 63, pp. 207–222, Apr. 2016
• R. Riikonen, "Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children," Int. J. Mol. Sci., vol. 18, no. 10, Sep. 2017
• A. B. Steinmetz, S. A. Stern, S. A. Kohtz, G. Descalzi, and C. M. Alberini, "Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice," J. Neurosci. Off. J. Soc. Neurosci., vol. 38, no. 4, pp. 1015–1029, 24 2018
• D. Ebrahim-Fakhari and M. Sahin, "Autism and the synapse: emerging mechanisms and mechanism-based therapies," Curr. Opin. Neurol., vol. 28, no. 2, pp. 91–102, Apr. 2015
• D. C. Gómedo, M. Beresiewicz, and B. Zablocka, "Neuroprotective effects of short peptides derived from the insulin-like growth factor 1," Neurochem. Int., vol. 51, no. 8, pp. 451–458, Dec. 2007
• M. M. Ramsey, M. M. Adams, O. J. Ariwodola, W. E. Sonntag, and J. L. Weiner, "Functional characterization of des-IGF-1 action at excitatory synapses in the CA1 region of rat hippocampus," J. Neurophysiol., vol. 94, no. 1, pp. 247–254, Jul. 2005
• X. Zhao, B. W. McBride, L. M. Trouten-Radford, and J. H. Burton, "Effects of intramuscular injection of insulin-like growth factor analogues on bovine hydrothermal protein release by neutrophils and basophils by mononuclear cells," J. Endocrinol., vol. 139, no. 2, pp. 245–252, Nov. 1993
• M. E. Yaleman, D. C. Clattey, S. C. Ceyfen-Hughes, V. J. Frost, J. A. Ward, and J. M. Holly, "Cytokines modulate the sensitivity of human fibroblasts to stimulation by insulin-like growth factor-I (IGF-I) by altering endogenous IGF-binding protein production," J. Endocrinol., vol. 137, no. 1, pp. 151–159, Apr. 1993
• M. Ramade-Bonnet, F. Gamouille, F. al Alie, M. Roccanilora, J. Menville, and G. Perilliere, "Effects of IGF-I and IGF-I on insulin-like growth factor-I/insulin receptor and its potential IGF-II autocrine loop, promotes the differentiation of human colon cancer cells," Int. J. Cancer, vol. 52, no. 3, pp. 457–473, Oct. 1992
• J Clin Invest. 2004;113(1):25-27. https://doi.org/10.1172/JCI200420660.